Company NeuroPace, Inc.

Equities

NPCE

US6412881053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
13.56 USD -3.21% Intraday chart for NeuroPace, Inc. -1.38% +31.52%

Business Summary

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

Number of employees: 171

Sales per Business

USD in Million2022Weight2023Weight Delta
Medical Device
100.0 %
46 100.0 % 65 100.0 % +43.72%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
46 100.0 % 65 100.0 % +43.72%

Managers

Managers TitleAgeSince
Chief Executive Officer 56 23-07-09
Founder 63 97-11-18
Founder 82 97-11-30
Chief Tech/Sci/R&D Officer 53 20-12-31
Chief Tech/Sci/R&D Officer 66 97-11-18
Investor Relations Contact - -
General Counsel - 22-11-30
Human Resources Officer 55 99-12-31
Corporate Officer/Principal 46 12-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 52 21-10-31
Director/Board Member 68 97-11-18
Founder 82 97-11-30
Director/Board Member 56 23-01-04
Director/Board Member 55 20-07-31
Chief Executive Officer 56 23-07-09
Director/Board Member 44 21-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,344,637 22,749,661 ( 80.26 %) 0 80.26 %

Shareholders

NameEquities%Valuation
KCK-US, Inc.
19.73 %
5,593,773 19.73 % 74 M $
A.M. Accelmed Management (2009) Ltd.
15.64 %
4,432,948 15.64 % 59 M $
OrbiMed Advisors Private Equity
12.35 %
3,501,975 12.35 % 46 M $
Morgan Stanley Capital Services LLC
8.681 %
2,460,716 8.681 % 32 M $
Soleus Capital Management LP
8.584 %
2,433,168 8.584 % 32 M $
Nantahala Capital Management LLC
4.141 %
1,173,677 4.141 % 15 M $
Kent Lake Capital LLC
2.367 %
670,946 2.367 % 9 M $
565,657 1.996 % 7 M $
Fidelity Management & Research Co. LLC
1.651 %
468,081 1.651 % 6 M $
Vanguard Global Advisers LLC
1.457 %
413,106 1.457 % 5 M $

Company contact information

NeuroPace, Inc.

455 North Bernardo Avenue

94043, Mountain View

+

http://www.neuropace.com
address NeuroPace, Inc.(NPCE)
  1. Stock Market
  2. Equities
  3. NPCE Stock
  4. Company NeuroPace, Inc.